Photo taken from ESMO/LinkedIn
May 24, 2024, 01:43
ESMO – In an interim analysis presented at ESMOBreast24 of atezolizumab and sacituzumab in locally advanced or metastatic triple-negative breast cancer
ESMO shared a post on LinkedIn:
“In an interim analysis presented at ESMOBreast24, first-line treatment with the combination of the PD-L1 inhibitor atezolizumab and sacituzumab govitecan showed a higher objective response rate compared to control in patients with previously untreated PD-L1 positive locally advanced or metastatic triple-negative breast cancer.”
Read further.
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 15, 2025, 11:08
Jan 15, 2025, 08:14
Jan 15, 2025, 07:53
Jan 15, 2025, 07:27
Jan 15, 2025, 07:22